Nemolizumab for teens and adults with moderate-to-severe eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study looks at how well nemolizumab works in everyday practice for people with moderate-to-severe atopic dermatitis (eczema). It helps researchers understand the real-world benefits and safety of this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 12 years old
- You must have moderate-to-severe atopic dermatitis (eczema)
- Your doctor has decided to start you on nemolizumab (brand name Nemluvio®) as part of your normal care
- You have not used any experimental (investigational) drug in the last 3 months
- You have never taken nemolizumab before
- You can understand the study information and fill out questionnaires
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies whether lebrikizumab is safe and continues to work over the long term for children and teens with moderate-to-severe atopic dermatitis (eczema). It’s meant for people who already finished a related earlier study and can safely continue.
This study tests a new injectable medicine (nemolizumab) for people with moderate-to-severe eczema that hasn't been helped enough by topical treatments. It aims to reduce itching and skin symptoms. The trial will compare the drug to a placebo in Chinese participants.
This study tests an oral medication (EC-18) for moderate to severe atopic dermatitis (eczema) to see if it can improve symptoms like itching and skin rash. It may be an option for people whose eczema is not controlled by topical treatments.
This trial tests if an ointment called QLM3003 is safe and helps adults with mild to moderate atopic dermatitis (eczema). It may be a new treatment option for people whose eczema affects small areas of skin.
This study tests an oral medicine called roflumilast to see if it helps treat moderate to severe eczema in people aged 12 and up who haven't used other systemic treatments recently. It's a pilot study to check both safety and how well it works.
This study looks at how well dupilumab works for children and teens with severe eczema (atopic dermatitis) even when the rash is not widespread. It aims to see if the treatment helps with itching, quality of life, and rashes in visible or sensitive areas.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.